Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK SjS-1 deucravacitinib in active Sjogren's syndrome
jRCT2031230582Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in Sjögren's syndrome (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change from baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index score at Week 52. Started Jan 2024; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2031230582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230582.